Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185848
Status:
COMPLETED
Last Update Posted:
2017-03-14
First Post:
2005-09-12
Brief Title:
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Sponsor:
Sanjiv Sam Gambhir
Organization:
Stanford University
Study Overview
Official Title:
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe 18FFHBG in Humans
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether 18FFHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials In this phase 1 study we will assess the safety and biodistribution of 18FFHBG in patients
Detailed Description:
The success of cell and gene therapy depends on specific targeting of the therapeutic gene or cell that is administered to the patient Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene or cell Imaging should help in the design of better protocols and potentially reduce side-effects of cell and gene therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 95908 | OTHER | None | None |
| BRNCNS0003 | OTHER | Stanford University | None |